普拉克索联合多巴丝肼片治疗帕金森病的临床观察

Clinical effect of pramipexole combined with levodopa and benserazide hydrochloride tablets on Parkinson disease

目的探讨普拉克索联合多巴丝肼片治疗帕金森病的临床效果。方法抽取2019年8月至2021年10月南阳南石医院收治的帕金森病患者78例,按照随机数字表法分为A组与B组,每组39例。B组采用多巴丝肼片治疗,A组在B组治疗基础上采用普拉克索治疗。比较两组临床效果、蒙特利尔认知评估量表(MOCA)、简易智能精神状态检查量表(MMSE)评分、统一帕金森病病评定量表(UPDRS)评分、过氧化氢酶(CAT)、总谷胱甘肽(T-GSH)、匹茨堡睡眠质量指数量表(PSQI)及不良反应发生率。结果A组总有效率(94.87%,37/39)高于B组(79.49%,31/39),P<0.05;治疗后,A组MOCA、MMSE评分高于B组(P<0.05);治疗后,A组日常活动、运动功能及情绪评分低于B组(P<0.05);治疗后,A组CAT、T-GSH水平高于B组(P<0.05);治疗后,A组睡眠质量评分低于B组(P<0.05);A组不良反应发生率(7.69%,3/39)与B组(10.26%,4/39)比较差异未见统计学意义(P>0.05)。结论普拉克索联合多巴丝肼片应用于帕金森病患者的治疗中,可缓解临床症状、减轻氧化应激,促进认知功能和睡眠质量提高,临床效果和安全性较好。

Objective To investigate the value of pramipexole combined with levodopa and benserazide hydrochloride tablets on Parkinson disease.Methods A total of 78 patients with Parkinson disease treated in Nanshi Hospital of Nanyang from August 2019 to October 2021 were selected,and they were divided into group A and group B according to random number table method,with 39 cases in each group.Group B was treated with levodopa and benserazide hydrochloride tablets,while group A was treated with pramipexole based on the treatment of group B.The clinical effects,Montreal Cognitive Assessment Scale(MOCA)score,Mini Mental State Examination Scale(MMSE)score,Unified Parkinson’s Disease Rating Scale(UPDRS)score,catalase(CAT),total glutathione(T-GSH),Pittsburgh sleep quality index(PSQI),and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the group A(94.87%,37/39)was higher than that in the group B(79.49%,31/39),P<0.05.After treatment,the scores of MOCA and MMSE in the group A were higher than those in the group B(P<0.05).After treatment,the scores of daily activities,motor function and emotion in the group A were lower than those in the group B(P<0.05).After treatment,the levels of CAT and T-GSH in the group A were higher than those in the group B(P<0.05).After treatment,the score of sleep quality in the group A was lower than that in group B(P<0.05).There was no significant difference in the incidence of adverse reactions between group A(7.69%,3/39)and group B(10.26%,4/39),P>0.05.Conclusions Pramipexole combined with levodopa and benserazide hydrochloride tablets can alleviate clinical symptoms,reduce oxidative stress,improve cognitive function and sleep quality in patients with Parkinson disease.It has good clinical effects and safety.